FDA slaps a hold on Agios’ PK drug, forcing the biotech to kill it in favor of an internal rival
A few days ago, Agios $AGIO was trying to decide whether it should take AG-348 or AG-519 into a pivotal trial for rare cases of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
